| 3.06 -0.21 (-6.42%) | 06-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.81 |
1-year : | 4.25 |
| Resists | First : | 3.26 |
Second : | 3.63 |
| Pivot price | 3.23  |
|||
| Supports | First : | 2.67 |
Second : | 2.22 |
| MAs | MA(5) : | 3.26 |
MA(20) : | 3.15 |
| MA(100) : | 3.29 |
MA(250) : | 5.08 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 45.2 |
D(3) : | 57.7 |
| RSI | RSI(14): 46.9 |
|||
| 52-week | High : | 10.72 | Low : | 1.77 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RLAY ] has closed above bottom band by 21.5%. Bollinger Bands are 39.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.3 - 3.32 | 3.32 - 3.33 |
| Low: | 2.99 - 3.01 | 3.01 - 3.03 |
| Close: | 3.03 - 3.06 | 3.06 - 3.09 |
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Thu, 12 Jun 2025
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors | RLAY Stock News - GuruFocus
Wed, 11 Jun 2025
Relay Therapeutics Appoints Claire Mazumdar To Board Of Directors - marketscreener.com
Wed, 11 Jun 2025
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors - Yahoo Finance
Mon, 09 Jun 2025
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory - Insider Monkey
Mon, 02 Jun 2025
Breakthrough: Relay's Cancer Drug Shows 11-Month Survival Benefit in Advanced Breast Cancer Patients - Stock Titan
Tue, 27 May 2025
Relay Therapeutics’ SWOT analysis: ai-driven biotech stock faces pivotal year - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 171 (M) |
| Held by Insiders | 1.1006e+008 (%) |
| Held by Institutions | 1.5 (%) |
| Shares Short | 18,360 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.7307e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 105.2 % |
| Return on Equity (ttm) | -28.9 % |
| Qtrly Rev. Growth | 7.68e+006 % |
| Gross Profit (p.s.) | -14.66 |
| Sales Per Share | -28.6 |
| EBITDA (p.s.) | -1.88157e+008 |
| Qtrly Earnings Growth | -2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -272 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.11 |
| Price to Cash Flow | 1.15 |
| Dividend | 0 |
| Forward Dividend | 2.316e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|